24 research outputs found
The role of microtubule movement in bidirectional organelle transport
We study the role of microtubule movement in bidirectional organelle
transport in Drosophila S2 cells and show that EGFP-tagged peroxisomes in cells
serve as sensitive probes of motor induced, noisy cytoskeletal motions.
Multiple peroxisomes move in unison over large time windows and show
correlations with microtubule tip positions, indicating rapid microtubule
fluctuations in the longitudinal direction. We report the first high-resolution
measurement of longitudinal microtubule fluctuations performed by tracing such
pairs of co-moving peroxisomes. The resulting picture shows that
motor-dependent longitudinal microtubule oscillations contribute significantly
to cargo movement along microtubules. Thus, contrary to the conventional view,
organelle transport cannot be described solely in terms of cargo movement along
stationary microtubule tracks, but instead includes a strong contribution from
the movement of the tracks.Comment: 24 pages, 5 figure
Anti-cancer drug validation: the contribution of tissue engineered models
Abstract Drug toxicity frequently goes concealed until clinical trials stage, which is the most challenging, dangerous and expensive stage of drug development. Both the cultures of cancer cells in traditional 2D assays and animal studies have limitations that cannot ever be unraveled by improvements in drug-testing protocols. A new generation of bioengineered tumors is now emerging in response to these limitations, with potential to transform drug screening by providing predictive models of tumors within their tissue context, for studies of drug safety and efficacy. Considering the NCI60, a panel of 60 cancer cell lines representative of 9 different cancer types: leukemia, lung, colorectal, central nervous system (CNS), melanoma, ovarian, renal, prostate and breast, we propose to review current Bstate of art^ on the 9 cancer types specifically addressing the 3D tissue models that have been developed and used in drug discovery processes as an alternative to complement their studyThis article is a result of the project FROnTHERA (NORTE-01-0145-FEDER-000023), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). This article was also supported by the EU Framework Programme for Research and Innovation HORIZON 2020 (H2020) under grant agreement n° 668983 — FoReCaST. FCT distinction attributed to Joaquim M. Oliveira (IF/00423/2012) and Vitor M. Correlo (IF/01214/2014) under the Investigator FCT program is also greatly acknowledged.info:eu-repo/semantics/publishedVersio